English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12190/12972 (94%)
Visitors : 983536 Online Users : 546
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
分子與基因醫學研究所
生技與藥物研究所
生醫工程與奈米醫學研究所
免疫醫學研究中心
神經及精神醫學研究中心
細胞及系統醫學研究所
感染症與疫苗研究所
群體健康科學研究所
癌症研究所
國家環境醫學研究所
國家蚊媒傳染病防治研究中心
高齡醫學暨健康福祉研究中心
論壇
生醫資源中心
研究生培育合作學程
核心儀器設施中心
病理核心實驗室
實驗動物中心
行政管理部門
圖書館
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
國家衛生研究院 NHRI
>
Items for Author
Loading...
Category
Loading community tree, please wait....
Year
Loading year class tree, please wait....
Items for Author "Kim, JW"
Return to Browse by Author
Showing 7 items.
Collection
Date
Title
Relation
Bitstream
[陳立宗] 會議論文/會議摘要
2022-11
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
-
[陳立宗] 會議論文/會議摘要
2022-09
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
-
[陳立宗] 會議論文/會議摘要
2022-02-01
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
-
[陳立宗] 會議論文/會議摘要
2019-02
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC)
-
[陳立宗] 期刊論文
2024-08
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
-
[陳立宗] 期刊論文
2023-11
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
-
[陳立宗] 期刊論文
2023-07
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
-
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback